Directors
|
| |
Age
|
| |
Year First
Became Director |
| |
Current
Public Boards |
|
Karen L. Shoos (Chair of the Board)
|
| |
68
|
| |
2001
|
| |
1
|
|
Anthony S. Marucci (Chief Executive Officer)
|
| |
60
|
| |
2008
|
| |
2
|
|
Keith L. Brownlie
|
| |
69
|
| |
2017
|
| |
1
|
|
Cheryl L. Cohen
|
| |
56
|
| |
Nominee
|
| |
3
|
|
Herbert J. Conrad
|
| |
89
|
| |
2008
|
| |
1
|
|
James J. Marino
|
| |
72
|
| |
2017
|
| |
2
|
|
Garry A. Neil, M.D.
|
| |
68
|
| |
Nominee
|
| |
1
|
|
Harry H. Penner, Jr.
|
| |
76
|
| |
1997
|
| |
1
|
|
Attributes, Experience and Skills
|
| |
Karen L.
Shoos |
| |
Anthony S.
Marucci |
| |
Keith L.
Brownlie |
| |
Cheryl L.
Cohen |
| |
Herbert J.
Conrad |
| |
James J.
Marino |
| |
Garry A.
Neil, M.D. |
| |
Harry H.
Penner, Jr. |
| ||||||||||||||||||||||||
Industry Experience
|
| | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| |
Executive/Leadership Experience
|
| | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| |
Scientific Research/Drug Development Experience
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
*
|
| | | | | | | |
Business Strategy/Operations Experience
|
| | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
Financial Experience
|
| | | | | | | | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| | | | | | | | | |
|
*
|
| | | | | | | | | |
|
*
|
| |
Commercial Experience
|
| | | | | | | | | | | | | | | | | | | | |
|
*
|
| | | |
|
*
|
| | | | | | | | | | | | | | | | | | | |
Mergers & Acquisitions Experience
|
| | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| |
Public Company Board Experience
|
| | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| | | |
|
*
|
| |
| |
Board Size:
Total Number of Directors & Nominees |
| | |
8 (includes two nominees)
|
| | ||||||||||||
| |
Gender:
|
| | |
Male
|
| | |
Female
|
| | |
Non-Binary
|
| | |
Gender
Undisclosed |
| |
| | Directors & Nominees | | | |
6 (includes
one nominee) |
| | |
2 (includes
one nominee) |
| | |
—
|
| | |
—
|
| |
| | Demographic Background: | | | | | | | | | | | | | | | | | | |
| | African American or Black | | | |
—
|
| | |
—
|
| | |
—
|
| | |
—
|
| |
| | Alaskan Native or Native American | | | |
—
|
| | |
—
|
| | |
—
|
| | |
—
|
| |
| | Asian | | | |
—
|
| | |
—
|
| | |
—
|
| | |
—
|
| |
| | Hispanic or Latinx | | | |
—
|
| | |
—
|
| | |
—
|
| | |
—
|
| |
| | Native Hawaiian or Pacific Islander | | | |
—
|
| | |
—
|
| | |
—
|
| | |
—
|
| |
| | White | | | |
6 (includes
one nominee) |
| | |
2 (includes
one nominee) |
| | |
—
|
| | |
—
|
| |
| | Two or More Races or Ethnicities | | | |
—
|
| | |
—
|
| | |
—
|
| | |
—
|
| |
| | LGBTQ+ | | | |
—
|
| | |
—
|
| | |
—
|
| | |
—
|
| |
| | Undisclosed | | | |
—
|
| | |
—
|
| | |
—
|
| | |
—
|
| |
Name of Individual
|
| |
Age
|
| |
Position and Office
|
|
Anthony S. Marucci | | |
60
|
| | President, Chief Executive Officer and Director | |
Tibor Keler, Ph.D. | | |
63
|
| | Executive Vice President and Chief Scientific Officer | |
Sarah Cavanaugh | | |
47
|
| |
Senior Vice President, Corporate Affairs and Administration
|
|
Elizabeth Crowley | | |
50
|
| |
Senior Vice President and Chief Product Development Officer
|
|
Margo Heath-Chiozzi, M.D. | | |
65
|
| | Senior Vice President, Regulatory Affairs | |
Freddy Jimenez | | |
53
|
| | Senior Vice President and General Counsel | |
Sam Martin | | |
51
|
| | Senior Vice President, Chief Financial Officer and Secretary | |
Ronald Pepin, Ph.D. | | |
66
|
| | Senior Vice President and Chief Business Officer | |
Richard Wright, Ph.D. | | |
58
|
| | Senior Vice President and Chief Commercial Officer | |
Diane C. Young, M.D. | | |
66
|
| | Senior Vice President, Chief Medical Officer | |
| Aclaris Therapeutics | | | RAPT Therapeutics | |
| Applied Molecular Transport | | | Rubius Therapeutics | |
| Chimerix, Inc. | | | Seres Therapeutics, Inc. | |
| Enanta Pharmaceuticals | | | Spero Therapeutics | |
| Evelo Biosciences | | | SQZ Biotechnologies Company | |
| Five Prime Therapeutics, Inc. | | | Summit Therapeutics | |
| Gritstone Oncology | | | Sutro Biopharma | |
| Inovio Pharmaceuticals | | | Syndax Pharmaceuticals, Inc. | |
| Mersana Therapeutics | | | Syros Pharmaceuticals | |
| Precision BioSciences | | | TCR2 Therapeutics | |
| Protagonist Therapeutics, Inc. | | | | |
| | |
Annual Salary
|
| | | | | | | | | | | | | |||||||||
Name
|
| |
As of December 31,
2021 |
| |
As of December 31,
2020 |
| |
Increase
$ |
| |
Increase
% |
| ||||||||||||
Anthony S. Marucci
|
| | | $ | 680,908 | | | | | $ | 657,882 | | | | | $ | 23,026 | | | | | | 3.5% | | |
Tibor Keler, Ph.D.
|
| | | $ | 483,645 | | | | | $ | 467,645 | | | | | $ | 16,000 | | | | | | 3.4% | | |
Freddy Jimenez
|
| | | $ | 391,230 | | | | | $ | 378,000 | | | | | $ | 13,230 | | | | | | 3.5% | | |
Sam Martin
|
| | | $ | 412,820 | | | | | $ | 398,860 | | | | | $ | 13,960 | | | | | | 3.5% | | |
Diane C. Young, M.D.
|
| | | $ | 438,141 | | | | | $ | 423,325 | | | | | $ | 14,816 | | | | | | 3.5% | | |
2021 Corporate Goals
|
| |
Relative
Weight |
| |
2021
Achievement |
| ||||||
Pipeline Development:
|
| | | | 50 | | | | | | 120% | | |
CDX-0159 | | | | | | | | | | | | | |
•
Deliver final results from Phase 1b CIndU trial
|
| | | | | | | | | | | | |
•
Deliver final results from Phase 1b CSU trial
|
| | | | | | | | | | | | |
•
Initiate Phase 1b prurigo nodularis (PN) trial
|
| | | | | | | | | | | | |
•
Successfully manufacture and introduce sub-Q formulation into the clinic
|
| | | | | | | | | | | | |
•
Prepare for initiation of Phase 2 in chronic urticaria
|
| | | | | | | | | | | | |
•
Continue to evaluate CDX-0159 disease opportunities through internal efforts/external collaborations
|
| | | | | | | | | | | | |
CDX-1140 | | | | | | | | | | | | | |
•
Deliver results in combination with pembro and from first stage of evaluation in combination with chemotherapy
|
| | | | | | | | | | | | |
•
Define future development strategy
|
| | | | | | | | | | | | |
•
Execute on Bridge grant commitments, including oversight of external clinical development and manufacture of CDX-301
|
| | | | | | | | | | | | |
CDX-527 | | | | | | | | | | | | | |
•
Complete enrollment in dose escalation portion of CDX-527 Phase 1 trial
|
| | | | | | | | | | | | |
•
Initiate Phase 1 study
|
| | | | | | | | | | | | |
•
Complete enrollment in initial dose expansion cohorts within CDX-527 Phase 1 trial
|
| | | | | | | | | | | | |
•
Define future development strategy
|
| | | | | | | | | | | | |
Earlier stage pipeline assets | | | | | | | | | | | | | |
•
Select follow on molecule (KIT bispecific) for development
|
| | | | | | | | | | | | |
•
Continued evaluation and development of next R&D targets
|
| | | | | | | | | | | | |
Business and Financial Operations:
|
| | | | 50 | | | | | | 120% | | |
•
Execute on D&I initiative focused on promoting inclusion and diversity broadly at Celldex and on exploring ways to ensure our industry has a robust and diverse talent pipeline
|
| | | | | | | | | | | | |
•
Preserve two years of cash (through 2023) even if burn increases with clinical success
|
| | | | | | | | | | | | |
•
Increase/maintain institutional ownership from 83% to 85%
|
| | | | | | | | | | | | |
•
Obtain term sheet for significant in/out-licensing, collaboration or M&A transaction, as appropriate
|
| | | | | | | | | | | | |
•
Provide sufficient cash to extend runway through 2024, as appropriate
|
| | | | | | | | | | | | |
Totals:
|
| | | | 100 | | | | | | 120% | | |
Name and Principal Position
|
| |
Years
|
| |
Salary
($) |
| |
Bonus
($)(1) |
| |
Stock
Awards ($) |
| |
Option
Awards ($)(2) |
| |
Non-Equity
Incentive Plan Compensation ($) |
| |
Change in
Pension Value and Nonqualified Deferred Compensation Earnings ($) |
| |
All Other
Compensation ($)(3) |
| |
Total
($) |
| |||||||||||||||||||||||||||
Anthony S. Marucci
|
| | | | 2021 | | | | | | 668,509 | | | | | | 490,254 | | | | | | — | | | | | | 4,868,797 | | | | | | — | | | | | | — | | | | | | 18,334 | | | | | | 6,045,894 | | |
President and Chief
|
| | | | 2020 | | | | | | 644,257 | | | | | | 395,000 | | | | | | — | | | | | | 1,950,788 | | | | | | — | | | | | | — | | | | | | 16,623 | | | | | | 3,006,668 | | |
Executive Officer
|
| | | | 2019 | | | | | | 619,478 | | | | | | 284,661 | | | | | | — | | | | | | 208,580 | | | | | | — | | | | | | — | | | | | | 15,601 | | | | | | 1,128,320 | | |
Tibor Keler., Ph.D.
|
| | | | 2021 | | | | | | 475,030 | | | | | | 265,000 | | | | | | — | | | | | | 1,977,949 | | | | | | — | | | | | | — | | | | | | 8,483 | | | | | | 2,726,462 | | |
Executive Vice President and
|
| | | | 2020 | | | | | | 457,405 | | | | | | 190,000 | | | | | | — | | | | | | 859,939 | | | | | | — | | | | | | — | | | | | | 7,508 | | | | | | 1,514,852 | | |
Chief Scientific Officer
|
| | | | 2019 | | | | | | 442,474 | | | | | | 135,549 | | | | | | — | | | | | | 125,148 | | | | | | — | | | | | | — | | | | | | 4,182 | | | | | | 707,353 | | |
Freddy Jimenez(4)
|
| | | | 2021 | | | | | | 382,208 | | | | | | 190,000 | | | | | | — | | | | | | 1,586,706 | | | | | | — | | | | | | — | | | | | | 7,490 | | | | | | 2,166,404 | | |
Senior Vice President and
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
General Counsel
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Sam Martin
|
| | | | 2021 | | | | | | 405,303 | | | | | | 205,000 | | | | | | — | | | | | | 1,847,535 | | | | | | — | | | | | | — | | | | | | 9,044 | | | | | | 2,466,882 | | |
Senior Vice President and
|
| | | | 2020 | | | | | | 391,397 | | | | | | 142,000 | | | | | | — | | | | | | 840,829 | | | | | | — | | | | | | — | | | | | | 8,671 | | | | | | 1,382,897 | | |
Chief Financial Officer
|
| | | | 2019 | | | | | | 374,231 | | | | | | 103,000 | | | | | | — | | | | | | 89,689 | | | | | | — | | | | | | — | | | | | | 8,097 | | | | | | 575,017 | | |
Diane C. Young, M.D.(5)
|
| | | | 2021 | | | | | | 430,163 | | | | | | 200,000 | | | | | | — | | | | | | 1,564,970 | | | | | | — | | | | | | — | | | | | | 5,834 | | | | | | 2,200,967 | | |
Senior Vice President,
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Chief Medical Officer
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | |
Estimated Future
Payouts Under Equity Incentive Plan Awards |
| |
All Other
Stock Awards: Number of Shares of Stock or Units (#) |
| |
All Other
Option Awards: Number of Securities Underlying Options (#) |
| |
Exercise or
Base Price of Option Awards ($/Sh)(1) |
| |
Grant Date
Fair Value of Stock and Option Awards ($)(2) |
| |||||||||||||||
Name
|
| |
Grant
Date |
| |
Threshold
(#) |
| |
Target
(#) |
| |
Maximum
(#) |
| ||||||||||||||||||||||||
Anthony S. Marucci
|
| | | | 6/17/21 | | | | | | | | | | | | | | | | | | 224,000 | | | | | | 28.00 | | | | | | 4,868,797 | | |
Tibor Keler, Ph.D.
|
| | | | 6/17/21 | | | | | | | | | | | | | | | | | | 91,000 | | | | | | 28.00 | | | | | | 1,977,949 | | |
Freddy Jimenez
|
| | | | 6/17/21 | | | | | | | | | | | | | | | | | | 73,000 | | | | | | 28.00 | | | | | | 1,586,706 | | |
Sam Martin
|
| | | | 6/17/21 | | | | | | | | | | | | | | | | | | 85,000 | | | | | | 28.00 | | | | | | 1,847,535 | | |
Diane Young, M.D.
|
| | | | 6/17/21 | | | | | | | | | | | | | | | | | | 72,000 | | | | | | 28.00 | | | | | | 1,564,970 | | |
| | |
Option Awards
|
| |
Stock Awards
|
| |||||||||||||||||||||||||||||||||
Name
|
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable |
| |
Number of
Securities Underlying Unexercised Options (#) Unexercisable |
| |
Equity
Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Number of
Shares or Units of Stock That Have Not Vested (#) |
| |
Market
Value of Shares or Units of Stock That Have Not Vested ($) |
| |
Equity
Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) |
| |
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested (#) |
| ||||||||||||
Anthony S. Marucci(1)
|
| | | | — | | | | | | 224,000 | | | | | | | | | 28.00 | | | | | | 6/17/31 | | | | | | | | | | | | | | |
Anthony S. Marucci(1)
|
| | | | 91,875 | | | | | | 153,125 | | | | | | | | | 10.38 | | | | | | 6/18/30 | | | | | | | | | | | | | | |
Anthony S. Marucci(1)
|
| | | | 62,500 | | | | | | 37,500 | | | | | | | | | 2.78 | | | | | | 6/19/29 | | | | | | | | | | | | | | |
Anthony S. Marucci(1)
|
| | | | 62,706 | | | | | | 8,959 | | | | | | | | | 9.02 | | | | | | 6/13/28 | | | | | | | | | | | | | | |
Anthony S. Marucci
|
| | | | 31,665 | | | | | | — | | | | | | | | | 34.80 | | | | | | 6/15/27 | | | | | | | | | | | | | | |
Anthony S. Marucci
|
| | | | 31,665 | | | | | | — | | | | | | | | | 70.80 | | | | | | 6/8/26 | | | | | | | | | | | | | | |
Anthony S. Marucci
|
| | | | 18,666 | | | | | | — | | | | | | | | | 381.15 | | | | | | 6/10/25 | | | | | | | | | | | | | | |
Anthony S. Marucci
|
| | | | 18,666 | | | | | | — | | | | | | | | | 201.75 | | | | | | 6/4/24 | | | | | | | | | | | | | | |
Anthony S. Marucci
|
| | | | 18,666 | | | | | | — | | | | | | | | | 245.40 | | | | | | 7/1/23 | | | | | | | | | | | | | | |
Anthony S. Marucci
|
| | | | 18,666 | | | | | | — | | | | | | | | | 85.35 | | | | | | 9/12/22 | | | | | | | | | | | | | | |
Tibor Keler, Ph.D.(1)
|
| | | | — | | | | | | 91,000 | | | | | | | | | 28.00 | | | | | | 6/17/31 | | | | | | | | | | | | | | |
| | |
Option Awards
|
| |
Stock Awards
|
| |||||||||||||||||||||||||||||||||
Name
|
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable |
| |
Number of
Securities Underlying Unexercised Options (#) Unexercisable |
| |
Equity
Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Number of
Shares or Units of Stock That Have Not Vested (#) |
| |
Market
Value of Shares or Units of Stock That Have Not Vested ($) |
| |
Equity
Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) |
| |
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested (#) |
| ||||||||||||
Tibor Keler, Ph.D.(1)
|
| | | | 40,500 | | | | | | 67,500 | | | | | | | | | 10.38 | | | | | | 6/18/30 | | | | | | | | | | | | | | |
Tibor Keler, Ph.D.(1)
|
| | | | 37,500 | | | | | | 22,500 | | | | | | | | | 2.78 | | | | | | 6/19/29 | | | | | | | | | | | | | | |
Tibor Keler, Ph.D.(1)
|
| | | | 22,749 | | | | | | 3,250 | | | | | | | | | 9.02 | | | | | | 6/13/28 | | | | | | | | | | | | | | |
Tibor Keler, Ph.D.
|
| | | | 10,799 | | | | | | — | | | | | | | | | 34.80 | | | | | | 6/15/27 | | | | | | | | | | | | | | |
Tibor Keler, Ph.D.
|
| | | | 10,799 | | | | | | — | | | | | | | | | 70.80 | | | | | | 6/8/26 | | | | | | | | | | | | | | |
Tibor Keler, Ph.D.
|
| | | | 7,766 | | | | | | — | | | | | | | | | 381.15 | | | | | | 6/10/25 | | | | | | | | | | | | | | |
Tibor Keler, Ph.D.
|
| | | | 7,766 | | | | | | — | | | | | | | | | 201.75 | | | | | | 6/4/24 | | | | | | | | | | | | | | |
Tibor Keler, Ph.D.
|
| | | | 7,666 | | | | | | — | | | | | | | | | 245.40 | | | | | | 7/1/23 | | | | | | | | | | | | | | |
Tibor Keler, Ph.D.
|
| | | | 7,666 | | | | | | — | | | | | | | | | 85.35 | | | | | | 9/12/22 | | | | | | | | | | | | | | |
Freddy Jimenez(1)
|
| | | | — | | | | | | 73,000 | | | | | | | | | 28.00 | | | | | | 6/17/31 | | | | | | | | | | | | | | |
Freddy Jimenez(1)
|
| | | | 13,500 | | | | | | 22,500 | | | | | | | | | 10.38 | | | | | | 6/18/30 | | | | | | | | | | | | | | |
Freddy Jimenez(1)
|
| | | | 12,500 | | | | | | 7,500 | | | | | | | | | 2.78 | | | | | | 6/19/29 | | | | | | | | | | | | | | |
Freddy Jimenez(1)
|
| | | | 3,645 | | | | | | 521 | | | | | | | | | 9.02 | | | | | | 6/13/28 | | | | | | | | | | | | | | |
Freddy Jimenez
|
| | | | 1,666 | | | | | | — | | | | | | | | | 34.80 | | | | | | 6/15/27 | | | | | | | | | | | | | | |
Freddy Jimenez
|
| | | | 266 | | | | | | — | | | | | | | | | 65.40 | | | | | | 8/11/26 | | | | | | | | | | | | | | |
Freddy Jimenez
|
| | | | 733 | | | | | | — | | | | | | | | | 70.80 | | | | | | 6/8/26 | | | | | | | | | | | | | | |
Freddy Jimenez
|
| | | | 1,400 | | | | | | — | | | | | | | | | 112.50 | | | | | | 3/1/26 | | | | | | | | | | | | | | |
Sam Martin(1)
|
| | | | — | | | | | | 85,000 | | | | | | | | | 28.00 | | | | | | 6/17/31 | | | | | | | | | | | | | | |
Sam Martin(1)
|
| | | | 39,600 | | | | | | 66,000 | | | | | | | | | 10.38 | | | | | | 6/18/30 | | | | | | | | | | | | | | |
Sam Martin(1)
|
| | | | 8,296 | | | | | | 16,125 | | | | | | | | | 2.78 | | | | | | 6/19/29 | | | | | | | | | | | | | | |
Sam Martin(1)
|
| | | | 6,238 | | | | | | 3,292 | | | | | | | | | 9.02 | | | | | | 6/13/28 | | | | | | | | | | | | | | |
Sam Martin
|
| | | | 4,332 | | | | | | — | | | | | | | | | 34.80 | | | | | | 6/15/27 | | | | | | | | | | | | | | |
Sam Martin
|
| | | | 1,399 | | | | | | — | | | | | | | | | 70.80 | | | | | | 6/8/26 | | | | | | | | | | | | | | |
Sam Martin
|
| | | | 1,399 | | | | | | — | | | | | | | | | 381.15 | | | | | | 6/10/25 | | | | | | | | | | | | | | |
Sam Martin
|
| | | | 799 | | | | | | — | | | | | | | | | 201.75 | | | | | | 6/4/24 | | | | | | | | | | | | | | |
Sam Martin
|
| | | | 500 | | | | | | — | | | | | | | | | 245.40 | | | | | | 7/1/23 | | | | | | | | | | | | | | |
Sam Martin
|
| | | | 350 | | | | | | — | | | | | | | | | 95.55 | | | | | | 9/20/22 | | | | | | | | | | | | | | |
Diane Young, M.D(1)
|
| | | | — | | | | | | 72,000 | | | | | | | | | 28.00 | | | | | | 6/17/31 | | | | | | | | | | | | | | |
Diane Young, M.D(1)
|
| | | | 22,400 | | | | | | 45,000 | | | | | | | | | 10.38 | | | | | | 6/18/30 | | | | | | | | | | | | | | |
Diane Young, M.D(1)
|
| | | | 33,750 | | | | | | 26,250 | | | | | | | | | 2.71 | | | | | | 7/8/29 | | | | | | | | | | | | | | |
| | |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||
Name
|
| |
Number of Shares
Acquired on Exercise (#) |
| |
Value Realized
on Exercise ($)(1) |
| |
Number of Shares
Acquired on Vesting (#) |
| |
Value Realized
on Vesting ($) |
| ||||||||||||
Anthony S. Marucci
|
| | | | 3,537 | | | | | | 20,161 | | | | | | — | | | | | | — | | |
Tibor Keler, Ph.D.
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Freddy Jimenez
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Sam Martin
|
| | | | 35,381 | | | | | | 1,386,246 | | | | | | — | | | | | | — | | |
Diane Young, M.D.
|
| | | | 4,600 | | | | | | 149,781 | | | | | | — | | | | | | — | | |
Executive benefits and payments upon termination
|
| |
Voluntary
resignation for no good reason |
| |
Voluntary
resignation for good reason(1) |
| |
Termination
by Celldex without cause(1) |
| |
Termination
by Celldex for cause |
| |
Voluntary termination
by the executive for good reason or termination by Celldex without cause in connection with or following change of control(2) |
| |||||||||||||||
Anthony S. Marucci | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Base Salary
|
| | | $ | — | | | | | $ | 1,361,816 | | | | | $ | 1,361,816 | | | | | $ | — | | | | | $ | 1,361,816 | | |
Bonus
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 980,508 | | |
Equity Awards Acceleration(3)
|
| | | | — | | | | | | 2,080,205 | | | | | | 2,080,205 | | | | | | — | | | | | | 8,320,820 | | |
Continuation of Health Benefits
|
| | | | — | | | | | | 40,176 | | | | | | 40,176 | | | | | | — | | | | | | 40,176 | | |
Total
|
| | | $ | — | | | | | $ | 3,482,197 | | | | | $ | 3,482,197 | | | | | $ | — | | | | | $ | 10,703,320 | | |
Tibor Keler, Ph.D. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Base Salary
|
| | | $ | — | | | | | $ | 483,645 | | | | | $ | 483,645 | | | | | $ | — | | | | | $ | 967,290 | | |
Bonus
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 397,500 | | |
Equity Awards Acceleration(3)
|
| | | | — | | | | | | 944,730 | | | | | | 944,730 | | | | | | — | | | | | | 3,778,916 | | |
Continuation of Health Benefits
|
| | | | — | | | | | | 29,646 | | | | | | 29,646 | | | | | | — | | | | | | 29,646 | | |
Total
|
| | | $ | — | | | | | $ | 1,458,021 | | | | | $ | 1,458,021 | | | | | $ | — | | | | | $ | 5,173,352 | | |
Freddy Jimenez | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Base Salary
|
| | | $ | — | | | | | $ | 391,230 | | | | | $ | 391,230 | | | | | $ | — | | | | | $ | 782,460 | | |
Bonus
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 285,000 | | |
Equity Awards Acceleration(3)
|
| | | | — | | | | | | 424,240 | | | | | | 424,240 | | | | | | — | | | | | | 1,696,954 | | |
Continuation of Health Benefits
|
| | | | — | | | | | | 40,176 | | | | | | 40,176 | | | | | | — | | | | | | 40,176 | | |
Total
|
| | | $ | — | | | | | $ | 855,646 | | | | | $ | 855,646 | | | | | $ | — | | | | | $ | 2,804,590 | | |
Sam Martin | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Base Salary
|
| | | $ | — | | | | | $ | 412,820 | | | | | $ | 412,820 | | | | | $ | — | | | | | $ | 825,640 | | |
Bonus
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 307,500 | | |
Equity Awards Acceleration(3)
|
| | | | — | | | | | | 861,331 | | | | | | 861,331 | | | | | | — | | | | | | 3,445,324 | | |
Continuation of Health Benefits
|
| | | | — | | | | | | 40,176 | | | | | | 40,176 | | | | | | — | | | | | | 40,176 | | |
Total
|
| | | $ | — | | | | | $ | 1,314,327 | | | | | $ | 1,314,327 | | | | | $ | — | | | | | $ | 4,618,640 | | |
Executive benefits and payments upon termination
|
| |
Voluntary
resignation for no good reason |
| |
Voluntary
resignation for good reason(1) |
| |
Termination
by Celldex without cause(1) |
| |
Termination
by Celldex for cause |
| |
Voluntary termination
by the executive for good reason or termination by Celldex without cause in connection with or following change of control(2) |
| |||||||||||||||
Diane Young, M.D. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Base Salary
|
| | | $ | — | | | | | $ | 438,141 | | | | | $ | 438,141 | | | | | $ | — | | | | | $ | 876,282 | | |
Bonus
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 300,000 | | |
Equity Awards Acceleration(3)
|
| | | | — | | | | | | 745,236 | | | | | | 745,236 | | | | | | — | | | | | | 2,980,943 | | |
Continuation of Health Benefits
|
| | | | — | | | | | | 13,410 | | | | | | 13,410 | | | | | | — | | | | | | 13,410 | | |
Total
|
| | | $ | — | | | | | $ | 1,196,787 | | | | | $ | 1,196,787 | | | | | $ | — | | | | | $ | 4,170,635 | | |
|
Level
|
| |
Minimum Required
Level of Stock Ownership |
|
CEO
|
| |
3 times annual base salary
|
|
Other Executive Officers
|
| |
1 times annual base salary
|
|
Name
|
| |
Fees
Earned or Paid in Cash ($) |
| |
Stock
Awards ($) |
| |
Option
Awards ($)(1) |
| |
Non-Equity
Incentive Plan Compensation ($) |
| |
Change in
Pension Value and Nonqualified Deferred Compensation Earnings |
| |
All Other
Compensation ($) |
| |
Total
($) |
| |||||||||||||||||||||
Karen L. Shoos
|
| | | | 74,000 | | | | | | — | | | | | | 260,828 | | | | | | — | | | | | | — | | | | | | — | | | | | | 334,828 | | |
Keith L. Brownlie
|
| | | | 59,000 | | | | | | — | | | | | | 260,828 | | | | | | — | | | | | | — | | | | | | — | | | | | | 319,828 | | |
Herbert J. Conrad
|
| | | | 54,250 | | | | | | — | | | | | | 260,828 | | | | | | — | | | | | | — | | | | | | — | | | | | | 315,078 | | |
James J. Marino
|
| | | | 60,000 | | | | | | — | | | | | | 260,828 | | | | | | — | | | | | | — | | | | | | — | | | | | | 320,828 | | |
Harry H. Penner, Jr.
|
| | | | 53,750 | | | | | | — | | | | | | 260,828 | | | | | | — | | | | | | — | | | | | | — | | | | | | 314,578 | | |
Name and Business Address of Beneficial Owners*
|
| |
Amount and Nature of
Beneficial Ownership(1) |
| |
Percentage of
Common Stock(2) |
| ||||||
5% Holders | | | | | | | | | | | | | |
FMR LLC
|
| | | | 6,999,580(3) | | | | | | 15.0% | | |
245 Summer Street
Boston, Massachusetts 02210 |
| | | | | | | | | | | | |
RTW Investments, LP
|
| | | | 3,921,579(4) | | | | | | 8.4% | | |
40 10th Avenue
7th Floor New York, NY 10014 |
| | | | | | | | | | | | |
BlackRock Inc.
|
| | | | 3,101,030(5) | | | | | | 6.6% | | |
55 East 52nd Street
New York, NY 10055 |
| | | | | | | | | | | | |
The Vanguard Group
|
| | | | 2,413,056(6) | | | | | | 5.2% | | |
100 Vanguard Blvd.
Malvern, PA 19355 |
| | | | | | | | | | | | |
State Street Corp
|
| | | | 2,368,040(7) | | | | | | 5.1% | | |
One Lincoln Street
Boston, MA 02111 |
| | | | | | | | | | | | |
Director Nominees and Named Executive Officers | | | | | | | | | | | | | |
Keith L. Brownlie
|
| | | | 22,165(8) | | | | | | ** | | |
Cheryl L. Cohen
|
| | | | — | | | | | | ** | | |
Herbert J. Conrad
|
| | | | 25,481(9) | | | | | | ** | | |
Freddy Jimenez
|
| | | | 37,900(10) | | | | | | ** | | |
Tibor Keler, Ph.D.
|
| | | | 172,693(11) | | | | | | ** | | |
James J. Marino
|
| | | | 34,203(12) | | | | | | ** | | |
Sam Martin
|
| | | | 98,224(13) | | | | | | ** | | |
Anthony S. Marucci
|
| | | | 408,511(14) | | | | | | ** | | |
Garry A. Neil, M.D.
|
| | | | — | | | | | | ** | | |
Harry H. Penner, Jr.
|
| | | | 25,708(15) | | | | | | ** | | |
Karen L. Shoos
|
| | | | 25,703(16) | | | | | | ** | | |
Diane C. Young, M.D.
|
| | | | 70,265(17) | | | | | | ** | | |
All Director Nominees and Executive Officers as a group
(17 persons) |
| | | | 1,303,981(18) | | | | | | 2.7% | | |
Plan Category
|
| |
(a)
Number of securities to be issued upon exercise of outstanding options and rights(1) |
| |
(b)
Weighted-average exercise price of outstanding options and rights |
| |
(c)
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) |
| |||||||||
Equity compensation plans approved by security
holders(2) |
| | | | 4,077,667(3) | | | | | $ | 30.02 | | | | | | 3,492,692(4) | | |
Fee Category
|
| |
2021
|
| |
2020
|
| ||||||
| | |
(In thousands)
|
| |||||||||
Audit Fees
|
| | | $ | 653 | | | | | $ | 745 | | |
Audit-Related Fees
|
| | | | — | | | | | | — | | |
Tax Fees
|
| | | | — | | | | | | — | | |
All Other Fees
|
| | | | 3 | | | | | | 3 | | |
Total Fees
|
| | | $ | 656 | | | | | $ | 748 | | |
D!
M\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+!
M LL"U0+@ NL"]0, PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#
MQP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P
M!/X%#044%]@8&!A8&)P8W!D@&
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M',P<]1T>'4<=:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@
M;""8(,0@\"$<(4@A=2&A( &YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"
M](-7@[J$'82 A..%1X6KA@Z&X !^8$D ]2HKS?4]>
MU%;^5U;8T,Q5%>XCBCVKC&Z)\,VY3G=N'4;<8%=%XDU,2RP0+/Y4,DDBRRQN
M%*M&NY4W\A23U!Y.,>N0#IJ*X:]U-_LEE$+MO)F=UDN0C(WR'Y5R?NYP02>3
MC<
/4G)/U/-
K:%[I
W;C/&,#%/5Y)KO3[F5IRH872!,)@B+S N1NR0F6R
M3QNP!P5WYM.MKF197C1G3&&95+#!R,$C(P>:&TZV=VD,:%I%VL2JY(( P3C)
M& .#0!F7M]/:R/$')PEHH)"YS-,\;-P ,X (XVY'W<9!C:ZNO,%LLIR+ORRY
M5"Q4VQE/ 7()X(&!@9#<@[(LH I38NTH$(VC&T9PN,=!DX'3DU'8QVCQ(8!
M&8U)*>6%V@\@D;>!U(./4^] &5J$TEYHUR68[E2Y7< ,D1,Z\\8^8+\V .IV
MXXP[5+NXM?.VR$?9;59>B?.3YF0WR]/W8^[MZGGIC:-M&4,>T;6W9&!@[B2V
M1T.23GUSS3)[*"Z97D16:,Y4LH)!XY!(XZ#IZ4 8UY>78:=DD "7,$2 H"!Y
MGD;B>A/WS@ @\GG[NT-U=6[.3*66&YAB *IEA+Y6XL0!T\SY=H7&/FW5KG[,
MTAB.S>V)"OR[CM( ?'7@J #VP/2B?[-!CS-B^9(OWMHW.,;>O5OE&._ QTH
MLT4V.-85"* %4 8 Z "G4 %%%1V]S'=H)(V#J>A4A@<''4<=: )**;)(L
M*EV("J"22< =233?M,?E^;N&S;NW9&W&,YSTQCG- $E%-CD690ZD%6 ((.0
M0>A!IU !1110 445&]S'$ZQLP#/G:"0"=HR<#J<#KB@"2BBB@ HHHH ***;)
M(L0RQ &0.3CEC@#\2<#WH =15235K2*7R6EC$F0-I=0V6Z#&<\YXJ>&YCN=V
MQ@VQBIVD'!'4''0CTH DHJI::M:7[;(98Y& SA'5CCUP"?6I#>P N"ZYB +_
M ##Y01D$\\<<\]J )Z*J1ZM:32")98R[ $*'4L01N! SGIS].:=#J-M3STQ8M-.MM/SY,:1[L9V*JYQTS@#.,TZTLH+!=D*+&I.<(H49]< #TH
M PHS-#=31K*P\^]"YPF5 M1)QE,?PA>0?E'][+'3L99KZT8;\.&FC#[03E'=
M%8C@$_*"1P">@ XJ:YLK3;(\J1[7 ,A=5P0G0L2.=O;/2G/""GD1DQ;57!10
M !G W*4[8Q@X'ID4 <3#X]N8@DL@ 6&/9,K!@YE(E*]%P,F(=L+O(.<95K>
M*M4L(S;R,#<828&6/9F,0F5UVJH'RE"N>I)/W2,CJ&\-*Z-&9G*R-N8&.VP2
M2#DCR,$Y Y-2?V$_F>;]HDW[=N[9;[L9SC/DYQGG% '*_P#";7EU/*D7RK<,
MJ6K.IV9#K&Q!V G(8MSG:1C!Z5J^&_$[ZU,97<)$(XHP" JM,XW-M+8.5^[M
MR<\&M&+PTL&S;,Z^5NV8CMAMW?>QB#C/?'6F1^'5E4,)I,,XEYBMU.\_QD&
M$-[GF@#*L-S/7G/S<<@
O+')/)Y/)K*N]-ENOM$;1Y62ZMW&2I5E7R0_&<\",
MY!'/;-;U% '/WVF7+2/*FX8NQ(/+,>\K]F$7'F97[Q.=V. 2.<9T]'M6M+<*
MV
!4T_3
M;M95DE!/^F&0EF0MM-J8P3L"KG=@$ <>K#YCT5% ')PZ3?QQ01;2 AM2P4Q!
M2(O*W;B079P5/0A=@7!)&TW+#3YDE53$4"7<\S.2F^:JXVL6SAU^\!P,9X
M /044 ;("/W@.5X&(V( !.W1T6_EU/=,P*+A%"'G#!=SG. >&;81V*'H20 "35
MK9I5259%C,#F3=(NY<;'4Y^9,<-G.>U-FL+F]MIH)I$/FQL@*1LN-RD$D&1L
M]?;_ RO%<3%V;>0!87GR_+C@1^V>
62^-C85E"Y)*YVC'(J_K,2-/$TJLT020?(KN0Y,>Q@$!8$ -AA]WU
M!(R 6M'2V^S));QB-)55P%55^\H/(7C.,59BN$F9U4Y,;;6Z\$J&Q^3 UQU]
M:7 L(56$F1+)-I,32.'"'(7YE$3+@'<>6. 2@%6;[3]LL^R(!3=H[Y@:160
MV^!E5QYG[TDX!.UOF([T =915#0X6@M55L]7(RNS +DJ A9BH ("J3D# (!X
M&1>6,\DL\$1_U<